China-based genetic testing provider 23Mofang has raised RMB100m ($15.8m) from a consortium including mobile-input technology producer Hanwang Technology, DealStreetAsia has reported.
The deal was led by venture capital firm Matrix Partners China and also featured ZhenFund as well as Yahui Medical Fund.
Founded in 2015, 23Mofang offers genetic testing services for individuals through a mobile app. The service has more than 150,000 users and includes tests for health risks and rare genetic diseases, as well as conditions particularly common to China.
The company has partnered science research and development firm ThermoFisher Scientific to create a biochip that makes it possible to test for more than 300 medical conditions for a maximum of RMB1,000 ($158).
23Mofang has now received $23m in funding overall, including $6m in an August 2017 series B round featuring Hanwang, Yahui Medical Fund, Chengdu Deshang Qidian Equity Investment and FundFenghou Capital.
The company had previously secured $2.9m in January the same year according to DealStreetAsia, though it has not disclosed the identity of the investors in that round.